Overview

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Status:
Recruiting
Trial end date:
2022-05-25
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies how well cabozantinib works in treating patients with kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
Emory University
Collaborator:
Exelixis